NewStem is a Bio-Platform company developing precision medicine therapeutics based on Synthetic Lethal interactions with cancer-related mutations causing genomic instability, and diagnostics for anti-cancer drug resistance.
The company Bio-Platform utilizes a proprietary Haploid human Pluripotent Stem Cells (HhPSCs) technology, as well as, deep bioinformatics.
NewStem is currently the only company worldwide to develop products based on this innovative HhPSCs technology. A paradigm-changing proprietary technology. (Nature, Sagi et al., 2016). These cells have the potential to change the face of genetic medical research as they are superior to cancer cell lines which dominate cancer research done today.
Our Team
CSO, Founder and Member of the Board
VP, R&D
Member of the Board